Genus (GENSF) NonCurrent Deferred Liabilities: $0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GENSF Genus PLC GENSF
71 GF Score
Price $31.07
GF Value $29.83
! 5 Warning Signs
View Full Analysis

What is Genus NonCurrent Deferred Liabilities?

Genus GENSF 71 NonCurrent Deferred Liabilities is $0.0 Mil as of Dec. 2025. GuruFocus rates GENSF with a GF Score™ of 71/100 and a GF Value™ of $29.83. The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Genus's non-current deferred liabilities for the quarter that ended in Dec. 2025 was $0.0 Mil.

Genus NonCurrent Deferred Liabilities Related Terms

Genus NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Genus's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genus NonCurrent Deferred Liabilities Chart

Genus Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genus Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GENSF
71GF Score
Genus PLC GENSF
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.0 Mil mean?
Genus (GENSF) has a NonCurrent Deferred Liabilities of $0.0 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Genus and its competitors.
Is Genus' NonCurrent Deferred Liabilities too high?
Genus' current NonCurrent Deferred Liabilities is $0.0 Mil. Overall, Genus has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Genus' NonCurrent Deferred Liabilities compare to VRTX and REGN?
Genus' NonCurrent Deferred Liabilities of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Genus and its competitors. Genus's current NonCurrent Deferred Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genus stock overvalued right now?
Genus (GENSF) has a current NonCurrent Deferred Liabilities of $0.0 Mil. The stock's GF Value™ is $29.83, compared to a current price of $31.07 — trading 4.1% above its estimated fair value. The current NonCurrent Deferred Liabilities is $0.0 Mil. Genus' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Genus (GENSF), the current NonCurrent Deferred Liabilities is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genus (GENSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genus stock appears to be overvalued. The current stock price of $31.07 is trading 4.1% above its estimated GF Value™ of $29.83.

Key valuation signals for GENSF:

  • NonCurrent Deferred Liabilities: $0.0 Mil
  • GF Value™: $29.83 vs. price of $31.07 (4.1% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the GENSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genus Business Description

Address Matrix House, Basing View, Basingstoke, Hampshire, GBR, RG21 4FF
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
71GF Score

Get the complete analysis for GENSF

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.07
Price
$29.83
GF Value